Protecting your intellectual property assets is essential to long-term success.
Our dedicated health sciences intellectual property team works with clients to protect leading-edge technologies, breakthrough products, market identities, and other core strategic assets.
Protecting intellectual property assets in the life sciences sector is an ongoing process. We assist clients with all aspects of patent counseling and protection, creating unique strategies through prosecution, lifecycle management, litigation, and regulatory exclusivity that helps clients drive value in the competitive life sciences marketplace. We advise on the interplay between FDA regulations and patent law on products, such as pharmaceuticals, nutraceuticals, and medical devices. We counsel pharmaceutical companies on novel patent issues related to drug development, including Orange Book listings, label claims, patent terms restoration, and extension. We also advise our clients on the subtle issues of written description, enablement, genus and species issues, and anticipation and obviousness in the "unpredictable arts."
Our team is one of the most active in state and federal courts throughout the U.S. and in post-grant proceedings before the Patent Trial and Appeal Board (PTAB). We frequently handle complex bet-the-company litigations, such as pharmaceutical and biotechnology patent matters, including Hatch-Waxman litigation and trade secret litigation, inventorship disputes, and related adversary proceedings before the USPTO. We create comprehensive strategies to manage parallel administrative proceedings, such as those before the USPTO. Our courtroom experience and scientific backgrounds enable us to realistically assess the chances of success in litigation, properly weigh settlement opportunities, and counsel our clients on strategic options.
Our team has represented clients involved in licensing, acquisition, and disposition transactions valued in billions of dollars in recent years. We assess intellectual property assets, conduct IP due diligence and audits, and negotiate agreements for major transactions, including mergers, acquisitions, and initial public offerings. We help global pharmaceutical and medical device companies with the IP aspects of both in- and out-licensing transactions and other commercialization efforts. We also frequently represent venture capital funds that target pharmaceutical and medical device companies, as well as universities and other research institutions seeking commercialization strategies for their innovations.
We help clients protect and strengthen their brands in a highly competitive marketplace, while often navigating a host of consumer protection regulations. Our work also includes representing companies in unfair competition matters and helping them resolve disputes with competitors and regulators across the U.S. and internationally.
We understand how vital competitive intelligence and other confidential information are to our clients. This is especially true for companies in the life sciences industry, where joint ventures, collaborative partnerships, and increased employee mobility are higher than average. Not only do we help our clients protect their trade secrets, but we also defend them against claims of trade secret theft.
Speaking Engagements
03.26.24
CROP Innovation & Business Conference 2024
Sponsored Events
03.22.24
New York Intellectual Property Law Association's (NYIPLA) 102nd Annual Dinner in Honor of the Federal Judiciary
Sponsored Events
03.20.24
INTA: The Business of AI
Articles + Publications
02.28.24
USPTO's Guidance on Inventorship of AI-Assisted Inventions Remains True to Fundamental Principles, But May Not Be the Right Test
Speaking Engagements
02.20.24
Nassau County Bar Association's Intellectual Property Committee Meeting
Speaking Engagements
02.18.24
AUTM 2024 Annual Meeting